NV3P Stock Chart & Stats
€0.93
€0.01(0.79%)
At close: 4:00 PM EDT
€0.93
€0.01(0.79%)
Day’s Range― - ―
52-Week Range€0.64 - €1.63
Previous CloseN/A
Volume0.00
Average Volume (3M)248.00
Market Cap
€29.58M
Enterprise Value€23.30M
Total Cash (Recent Filing)€2.79M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Nov 23, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding25,525,000
10 Day Avg. Volume530
30 Day Avg. Volume248
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.35Price Target Upside475.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal Financial LeverageMinimal debt reduces refinancing and interest-rate exposure while preserving financial flexibility relative to a highly leveraged biotechnology company. This balance-sheet advantage may help NanoViricides direct available capital toward research and clinical development rather than servicing substantial borrowing obligations.
In-house Manufacturing CapabilityOwning a cGMP-capable manufacturing and R&D facility can lower dependence on external production and create cost savings as clinical programs advance. Internal capabilities may also improve control over process development, formulation work, and preparation of drug supplies for later-stage trials.
Advancing Antiviral PipelineRegulatory clearances and the start of Phase II enrollment represent meaningful progression from preclinical development toward clinical validation. Multiple indications and FDA orphan-related designations broaden NV-387’s potential development pathways, although commercial value still depends on trial outcomes.
Bears Say
No Revenue And Persistent LossesA zero-revenue profile and recurring operating losses show that the company has not yet established a commercial revenue base to fund its activities. Continued losses leave future progress dependent on external capital or successful development and commercialization of investigational antiviral candidates.
Persistent Cash Burn And Going-concern RiskSustained negative operating and free cash flow means current programs consume cash rather than finance themselves. Management’s stated funding shortfall through September 2027 and substantial doubt about going-concern status indicate a durable risk that planned clinical and regulatory work may require additional financing or reprioritization.
Dependence On Equity FinancingRepeated equity and warrant financing provides liquidity but makes the development plan reliant on continued capital-market access. Additional share issuance can dilute existing holders, while funding uncertainty may constrain the pace of trials, manufacturing investment, and other long-term pipeline priorities.
NanoViricides News
NV3P FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was €0.64 and its highest was €1.63 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is €29.58M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 23, 2026 which is in 33 days.
How were NanoViricides’s earnings last quarter?
NanoViricides released its earnings results on Nov 24, 2025. The company reported -€0.116 earnings per share for the quarter, beating the consensus estimate of -€0.155 by €0.039.
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Undervalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate is -0.09.
How many shares outstanding does NanoViricides have?
NanoViricides has 25,525,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
NanoViricides reported an EPS of -€0.116 in its last earnings report, beating expectations of -€0.155. Following the earnings report the stock price went down -4.673%.
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in DE:NV3P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NanoViricides Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.33%
12-Months-Change
Fundamentals
Return on Equity
>-0.01%
Trailing 12-Months
Asset Growth
11.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NanoViricides
NanoViricides, Inc. operates as a nano-biopharmaceutical entity, specializing in the research, development, and market introduction of pharmaceutical solutions to combat viral infections. The company's robust product pipeline includes a Human Coronavirus Program, specifically engineered to tackle both COVID-19 and various seasonal coronaviruses. For herpes-related conditions, it offers HerpeCide in multiple forms: dermal topical and eye drops to treat ailments such as shingles, postherpetic neuralgia (PHN), chickenpox, recurrent herpes labialis, genital herpes, and ocular herpes keratitis. An intraocular injectable version of HerpeCide is also under development for viral acute retinal necrosis. Another significant therapeutic candidate is FluCide, a broad-spectrum anti-influenza nanoviricide, designed for both hospitalized patients via injection and outpatients through an oral formulation. NanoViricides also develops specialized nanoviricide eye drops for viral diseases affecting the external eye, DengueCide for various strains of Dengue viruses, and HIVCide, an anti-HIV nanoviricide specifically engineered to resist viral escape. Furthermore, the company is actively advancing additional nanoviricide drug projects targeting a diverse range of viruses and indications, alongside expanding its HerpeCide program to encompass a broader spectrum of herpes viruses and associated conditions. NanoViricides, Inc. was established in 2005 and maintains its corporate headquarters in Shelton, Connecticut.
NV3P Stock 12 Month Forecast
Average Price Target
€5.35
▲(475.69% Upside)